Your email has been successfully added to our mailing list.

×
0 0 0 0 -5.95663569215565E-05 -5.95663569215565E-05 -0.000476530855372791 -0.00226352156302118
Stock impact report

Sage CEO hopes experimental depression drug will be as big as Prozac [CNBC]

Sage Therapeutics, Inc. (SAGE) 
Last sage therapeutics, inc. earnings: 2/27 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.sagerx.com/investor-relations
Company Research Source: CNBC
Sage Therapeutics CEO Jeff Jonas is optimistic about a drug the company is developing to treat major depressive disorder. Recent positive trial results have given the company reason for encouragement. An estimated 16 million adults in the U.S. suffer from major depressive disorder, making for a large market potential for the drug. Published 2 Hours Ago Updated 16 Mins Ago CNBC.com Show less Read more
Impact Snapshot
Event Time:
SAGE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
SAGE alerts

from News Quantified
Opt-in for
SAGE alerts

from News Quantified